News Archive

Alvogen is pleased to announce the appointment of Joo-Hyung Lee as CEO of Kunwha Pharmaceuticals in South-Korea. 

Alvogen’s Chief Operating Officer, Elin Gabriel, has been named one of the first STEP (Science, Technology, Engineering and Production) honorees. She accepted her award at a ceremony in Washington DC, on February 5.

Alvogen, the international pharmaceuticals company, today announces that it has acquired Labormed Pharmaceuticals (“Labormed”) as of December 2012

In October, Alvogen participated in the world’s largest pharmaceutical fair, CPhI, for this first time.

Alvogen announced today that it has entered into an agreement to acquire a majority share in Kunwha Pharmaceuticals (“Kunwha”) through a combination of new shares issued by Kunwha to Alvogen and the acquisition of shares owned by Mr. Hongsun Chang, Kunwha´s Chairman and related parties. 

Alvogen Croatia is leading a kayaking tour along the beautiful Adriatic coast, aimed to inspire people to take action and help children battling cancer.

Alvogen will be sponsoring two rising athletes from Serbia and Bosnia & Herzegovinia: Damir Fejzic, a Vrsac (Serbia) native is playing in the Olympic Games this summer as the youngest taekwondo participant in London, and Bosnian and Herzegovinian tennis player Damir Dzumhur, who currently plays in the Wimbledon qualifying rounds.

Alvogen has entered into a collaboration with Columbia University and a group if distinguished scientists from all over the world, representing different academic disciplines. Alvogen is one of the official sponsors of the Life Course Project (Longitudinal Investigation for Epigenetic Causes and Outcomes in the Urban and Rural Social Environments). 

Robert Wessman, Chairman and CEO of Alvogen, will be a keynote speaker at the 4th Annual World Generic Medicines Congress Americas, in Washington DC. His presentation, "Winning Strategies", will be on November 15 at 9:45 AM, at the Westin Georgetown Hotel.

Speakers list also includes Henry Waxman, a member of the US Congress, Diem Nguyen, VP of Commerical Development of Biosimilars at Pfizer and Subir Basak, CEO of Intas Biopharma.

Alvogen today announced that its subsidiary, Alvogen Romania, has launched generic versions of three oncology products: exemestane, irinotecan and letrozole.

Doug Drysdale, Alvogen’s CEO, has been named one of Pharmaceutical Executive’s emerging pharma leaders for 2011.

Link to the full article

Robert Wessman, Executive Chairman of Alvogen will be a keynote speaker at the 5th Annual World Generic Medicines Congress Europe, in London. 

- 180-day marketing exclusivity expected
- U.S. brand sales in excess of US$1 billion
- Complements a fast growing U.S. pipeline of over 70 drugs

Alvogen, today announced that it has successfully closed a private placement financing.

Alvogen has opened a new research and development facility aimed at developing first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals.

Alvogen Inc. (“Alvogen”), the US-based generic pharmaceuticals company, today announced that it has expanded its operations in India, by establishing own clinical research organization (“CRO”) and...

Alvogen Inc. the US-based generic pharmaceutical company, today announces that three new top executives have joined its Executive Board. The new executives have an outstanding track record in the generic industry ...

As part of the agreement, Alvogen and Par have entered into a multi-year agreement for the development of several high-value, first-to-file generic product opportunities.

Initial Acquisition Reflects Specialty Generics Company's Focus on
Filling Niche Between Branded Pharmaceuticals and Commoditized Generics.